
Topical ruxolitinib shows sustained repigmentation over years, while oral JAK inhibitors move toward approval for widespread disease, George Martin, MD, says.

George Martin, MD, a dermatologist at the Dermatology and Laser Center of Maui and the co-founder of Scholars in Medicine and Maui Dermatology.